Laekna IPO hopes to hitch a ride on Novartis ties
The producer of drugs licensed from third parties is banking on ties to the Swiss drug maker, as one of its key products nears the regulatory finish line Key Takeaways:…
With Zero Revenue, Laekna Plays Chicken-And-Egg Game With Investors
The biotechnology company, which is facing ballooning losses without any revenue like many of its peers, has filed for an IPO in Hong Kong (more…)
Jiangsu Recbio Shoots to Become Hong Kong’s First HPV Vaccine Stock
The vaccine producer is making a second attempt to list in Hong Kong, as its core HPV vaccine undergoes Phase 3 clinical trials Key takeaways: Jiangsu Recbio has filed a…
RELATED ARTICLES
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG -
Adlai Nortye dives in Nasdaq debut, as key product faces hurdles
ANL.US
- ProfoundBio discovers the joys of having a wealthy owner
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
FAST NEWS: Beigene stock falls after Novartis terminates partnership
BGNE.US 6160.HK
